The STEP 1 trial, published in the New England Journal of Medicine in 2021, showed that participants taking semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group
It works by targeting two hormones, GIP and GLP-1 , which help the body manage blood sugar, reduce hunger, and increase feelings of fullness
Hasegawa M, Takahashi H, Rajabi H, et al
Dual agonists produce more weight loss on average in clinical trials, making them objectively more effective for total weight loss
This kind of thoughtful, ongoing care doesnt just make the experience more comfortable
Routinely tested for purity and potency, ensuring high quality versus over-the-counter brands